No holiday gift for GSK: FDA sends long-acting HIV injectable back to work

HIV patients hunting for relief from the burden of daily pills should wait longer.

Saturday, GlaxoSmithKline’s ViiV Healthcare declared that the FDA had rejected its long-acting HIV injection, known underneath of the working title Cabenuva. The statement is thin on details, noting with the exception that large response letter pertains to chemistry manufacturing and controls (CMC), which happens to be about data generated for the manufacturing process and product testing.

A ViiV spokesperson confirmed to FiercePharma which the FDA’s concerns tend not to include the should generate more clinical data but declined offer learn more. The firm said it would “work closely with the FDA to find the acceptable next steps” for your application.

Researchers are frequently incapable of access to the information they should get. And, even when data is at risk of getting merged, researchers find that it is challenging to go through it all and make understanding it to confidently draw the right conclusions and share the right results. Discover how to easily find, synthesize, and share information—speeding up and improving R&D.

Prescription is comprised of GSK’s integrase strand transfer inhibitor cabotegravir and Johnson & Johnson’s non-nucleoside reverse transcriptase inhibitor rilvipivirin, sold as Edurant in its tablet form. The GSK component is currently being produced with the company’s Barnard Castle factory in the U.K., the spokesperson said.

While existing HIV antiretroviral therapies require patients to accept daily medications to monitor the herpes virus, the new combo will allow them to receive an injection within the muscle every thirty days. Reduced dosing frequency could help ease the notion of fear of forgetting a dose and enhance compliance.

In two-phase 3 studies, Cabenuva showed it might, unfortunately, meet up standard-of-care, daily, oral three-drug regimens at suppressing HIV. Inside the Atlas study, prescription successfully contained herpes in 92.5% of patients after 48 weeks, while 95.5% of individuals throughout the three-drug regimen had undetectable viral loads. Among the Flair trial, the injectable’s 48-week virologic suppression rate hit 93.6%, as ViiV’s own therapy Triumeq (abacavir/dolutegravir/lamivudine) reached 93.3%.

Traditionally, a comprehensive HIV regimen contains three ingredients. GSK is aiming to save money the number of drugs HIV patients need to take, having already brought to market dual-drug regimens Juluca and Dovato. Juluca combines GSK’s integrase inhibitor Tivicay (dolutegravir) and Edurant, and it is approved to treat patients already virally suppressed. Dovato recommended for treatment-naïve adults, uses Tivicay and widely used off-patent lamivudine.

In Cabenuva’s Flair and Atlas trials, investigators observed high rates of injection site reaction. But execs have stressed that most events were manageable and produced very few patient withdrawals from the trial.

Within its Saturday statement, the GSK unit said the CMC problem is not just regarding safety so that there’s been no change to the security profile of the drug found in research studies. ViiV at this moment following both trials for more extended periods.

Meanwhile, it’s running the Atlas-2M study, which is testing the drug through bimonthly injections. That phase 3 trial recently reported positive results, showing comparable efficacy between both dosage forms.

ViiV has other HIV drug applications before the FDA, including for children-friendly product of dolutegravir and maybe for fostemsavir, a first-in-class attachment inhibitor for adults with multidrug-resistant HIV.

Still, GSK’s aim of challenging Gilead Sciences’ lead within the HIV market mainly depends on the success of two-drug regimens. To date, it must even to grab significant steam against Gilead’s fast-growing Biktarvy. In the first nine months, Gilead grew HIV sales by 12.3% a year over a year to $11.86 billion, and GSK’s £3.60 billion ($4.69 billion) only represented a 1% increase.

Author Resource Box:
No holiday gift for GSK: FDA sends long-acting HIV …. https://www.fiercepharma.com/pharma/no-christmas-gift-for-gsk-fda-sends-long-acting-hiv-injectable-back-to-work
Lime electric-assist bikes to launch in London – The Irish …. https://www.irishnews.com/magazine/technology/2018/12/06/news/lime-electric-assist-bikes-to-launch-in-london-1502732/

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s